Study Title

Iomab-ACT: A Pilot Study of 131-I Apamistamab Followed by CD19-Targeted CAR T-Cell Therapy for Patients With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia or Diffuse Large B-Cell Lymphoma

Study Details

Description:

This is a single-cohort pilot study; patients will receive 131-I apamistamab 75 mCi prior to CAR T-cell infusion in order to determine the maximum tolerated dose of 131-I apamistamab.

Sponsor:

Memorial Sloan Kettering Cancer Center

Government Study Link:

NCT04512716 - Click here to see study on

ClinicalTrials.gov

© 2021 XCancer Software LLC

Contact XCancer: 402-991-8468